Dr. Ekman joined Sophiris as Chairman in November 2010 and accepted the role of Executive Chairman in April 2011. Dr. Ekman is an Advisor of Warburg Pincus and Executive Partner of Sofinnova Ventures.

During 2001 to 2007, Dr. Ekman was EVP & President of R & D at Elan Pharmaceuticals where he advanced Elan’s drug development pipeline by securing four US New Drug Applications, three European Marketing Authorization Applications and five Investigational New Drug applications. Prior to joining Elan, Dr. Ekman was EVP, R and D at Schwartz Pharma AG (now UCB) and held executive R&D roles at Pharmacia (now Pfizer) from 1984-1997. Dr. Ekman is a director of Cebix Inc, InterMune Inc., Ocera Therapeutics, Inc., Elan and Amarin Corporation.

Dr. Ekman is a board certified surgeon with a Ph.D.in experimental biology. He obtained his Ph.D. and M.D. from the University of Gothenburg, Sweden.

Mr. Woods joined Sophiris as President and Chief Executive Officer in October 2012.

Mr. Woods is a serial life science entrepreneur, pharmaceutical and biotechnology executive. Mr. Woods brings 40 years of experience to the biotech/pharmaceutical arena, and currently serves as the Chief Executive Officer of Sophiris Bio, a biotechnology company focused on the development of urological drugs. He also served as President and CEO at NovaCardia, Inc. prior to its acquisition by Merck & Co., and nearly eight years as the Chief Executive Officer of Corvas International, Inc., a publicly traded biopharmaceutical company focused on cardiovascular disease and cancer, acquired by Dendreon. Prior to Corvas, Mr. Woods was President of Boehringer Mannheim’s US Pharmaceutical operations and spent over 20 years at Eli Lilly & Company in sales and marketing positions. Mr. Woods served as the Chairman for the Advisory Board of the University of California, San Diego’s Sulpizio Family Cardiovascular Center and has been the Chairman of the Board of Directors for BIOCOM, a life science industry association in Southern California.

He also serves on the Board of Arena Pharmaceuticals as well as being Chairman of the Board for Sorbent Therapeutics. Mr. Woods has a Bachelor’s Degree in Biology and Chemistry and a Master’s Degree in Marketing.

Noah J. Knauf is an investment professional at Warburg Pincus, where he is a member of the Healthcare Group and is based in the firm’s San Francisco office.

Mr. Knauff currently serves on the board of directors of ITC, a point-of-care diagnostics company; Keystone Dental, a global dental implant company; RegionalCare Hospital Partners, a non-urban hospital company; and on the board of directors of three development stage companies: Home Dialysis Plus, a kidney dialysis technology company; Silk Road Medical, a neurovascular medical device startup; Constitution Medical, a hematology in vitro diagnostics company. Prior to joining Warburg Pincus, Noah worked as an investment professional at Parthenon Capital, a middle market private equity firm and as a consultant at Bain & Company.

Mr. Knauff received a B.S. summa cum laude in Business Administration from the University of Arizona and a Masters in Business Administration from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar.

Mr. Heppell is a founding Partner, President and Chief Executive Officer of Catalyst Corporate Finance Lawyers of Vancouver, British Columbia.

Most recently, he has focused on investing in BC life science companies, initially as an active angel investor and now as a venture capitalist. Mr. Heppell is President and Fund Manager of Life Sciences for BC Advantage Funds (VCC) Ltd., which is a venture fund dedicated to investing in early-stage life science and technology companies in British Columbia. He is also Chairman of the Board of Inovio Biomedical Corporation based in San Diego. In addition to his activities in the British Columbia’s life science industry, Mr. Heppell is also the Managing Director-Western Canada of Gold Medal Plates, a partner of the Canadian Olympic Committee, committed to raising money for Canadian athletes training for the Olympics.

Mr. Heppell has a Bachelor of Science degree in Microbiology and an LL.B. from the University of British Columbia.

Dr. Geltosky is currently Managing Director of JEG and Associates, LLC, a business development consultancy firm focused on biotech and pharmaceuticals.

Dr. Geltosky is currently a member of the Commercialization Review Council of the Cancer Prevention and Research Institute of Texas (CPRIT). From October 2007 to June 2011, Jack served as Senior VP of Business Development for Arizona Technology Enterprises, the technology transfer arm of Arizona State University. Previously, Dr. Geltosky was Vice President of External Science, Technology and Licensing at Bristol Myers Squibb (“BMS”) where he was responsible for the acquisition and licensing as well as coordinating due diligence efforts on potential in- and out-licensing candidates. Jack was also Vice President, Scientific Licensing, Worldwide Business Development at SmithKline Beecham (now GlaxoSmithKline). For 10 years, he held roles of increasing responsibility within Johnson & Johnson.

Dr. Geltosky began his career as a research scientist at E.I. DuPont. Dr. Geltosky holds a B.S. in chemistry from Memphis State University and a Ph.D. in biochemistry from the California Institute of Technology.

Mr. Rohn has over 30 years of experience as a senior executive in the pharmaceutical and biotech industry.

He retired in January of 2005 from the position of Chief Operating Officer at Biogen-Idec, a major global biotech company. Mr. Rohn played an instrumental role in the $6.8 billion merger of IDEC Pharmaceuticals and Biogen Inc. Prior to serving as COO of the combined company, Mr. Rohn was the President and Chief Operating Officer of IDEC Pharmaceuticals where he helped transform IDEC from a small research organization into a very successful, biotechnology company. Mr. Rohn previously held a variety of commercial operating roles of increasing responsibilities at Abbott Laboratories, Bristol-Myers Squibb Co., and Adria Laboratories (now part of Pfizer).

Mr. Rohn also serves on the Board of Directors of Cebix Inc., Hansen Medical and the La Jolla Institute for Allergy and Immunology.

Mr. Sobti is a Principal at Warburg Pincus where he focuses on investments in the healthcare sector. Prior to joining Warburg Pincus in 2004, he worked at Rhône Capital, a middle market private equity firm, and at Merrill Lynch in the Mergers & Acquisitions group. Mr. Sobti received an A.B. in Business Economics and an A.B. in Computer Science from Brown University. In addition to his role at Sophiris, Mr. Sobti also serves on the Board of Directors of ReSearch Pharmaceutical Services, Inc.